TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37094988
Drug: Intravenous enadenotucirev
Normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enadenotucirev plus nivolumab
Study: 37095120
Drug: Single-target CD19
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-target CD19 CAR T-cell therapy
Study: 37095120
Drug: Dual-target tandem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-target tandem CD19/CD22 CAR T-cell therapy
Study: 37095120
Drug: Dual-target sequential
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-target sequential CD19/CD22 CAR T-cell therapy
Study: 37095250
Drug: Tau-targeting antisense
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau-targeting antisense oligonucleotide (MAPT), dosage and duration not specified
Study: 37095298
Drug: Bivalirudin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin use during operation (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Study: 37095298
Drug: Bivalirudin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Study: 37095378
Drug: Adenoviral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral and inactivated-virus vaccines (heterologous combinations)
Study: 37095378
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine as the second dose
Study: 37095378
Drug: Inactivated-virus vaccine
Normalized name: Japanese Encephalitis Virus Vaccine Inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated-virus vaccine (priming)
Study: 37095378
Drug: Boosting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosting with inactivated-virus vaccine
Study: 37095378
Drug: Different vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different vaccine combinations
Study: 37095561
Drug: Integrated HCV
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated HCV treatment
Study: 37095561
Drug: Standard HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HCV treatment
Study: 37095571
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted motivational interviewing with cognitive behavior therapy and mindfulness-based relapse prevention, delivered weekly over a period of 12 weeks.
Study: 37095689
Drug: Third-dose triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose triple combination therapy (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Study: 37095689
Drug: Third-dose dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose dual combination therapy (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg)
Study: 37095689
Drug: Third-dose dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose dual combination therapy (LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Study: 37095689
Drug: Third-dose dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose dual combination therapy (AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg)
Study: 37095689
Drug: Third-dose triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-dose triple combination therapy (ALC group)
Study: 37096093
Drug: Transbronchial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transbronchial injection of iron sucrose, median injection 90 mL (range, 70-120 mL)
Study: 37096186
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of raw walnut kernels for 6 months
Study: 37096188
Drug: Gumarontinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gumarontinib monotherapy
Study: 37096402
Drug: Total postoperative
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total postoperative opioid dose (TPOD)
Study: 37096402
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil dose on postoperative day 1 (POD1)
Study: 37096402
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with basal infusion
Study: 37096495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo, autologous FMT, no intervention, or antibiotics)
Study: 37097604
Drug: Nadroparin 5.900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 5.900 IU subcutaneously twice daily in mechanically ventilated patients
Study: 37097604
Drug: Nadroparin 5.900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 5.900 IU subcutaneously once daily in patients supplemented with conventional oxygen
Study: 37097715
Drug: Pembrolizumab administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab administered three-times weekly for 1 year or until progression, starting 30-45 days after TACE.
Study: 37098004
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acids (BCAA) intake measured in grams (g) per 1000 kilocalories (kcal) of energy intake (range 3.0-34.8 g/1000 kcal)
Study: 37098131
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg for 4 weeks)
Study: 37098409
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg prucalopride for 6 days
Study: 37098506
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment approaches for problem gambling
Study: 37098529
Drug: Olipudase alfa
Normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olipudase alfa enzyme replacement therapy
Study: 37099280
Drug: Cytoreduction plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes)
Study: 37099280
Drug: Cytoreduction plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes) in pT4 subgroup
Study: 37099295
Drug: IM tixagevimab-cilgavimab
Normalized name: CILGAVIMAB/TIXAGEVIMAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM tixagevimab-cilgavimab (300 mg IV or 600 mg IM)
Study: 37099295
Drug: IV tixagevimab-cilgavimab
Normalized name: CILGAVIMAB/TIXAGEVIMAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tixagevimab-cilgavimab (300 mg IV)
Study: 37099298
Drug: Repeated low-level
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated low-level red light (RLRL) therapy, twice per day, 5 days per week, each session lasting 3 minutes.
Study: 37099298
Drug: RLRL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLRL therapy (for those without treatment interruption due to COVID-19).
Study: 37099341
Drug: BCG-Denmark vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-Denmark vaccine
Study: 37099363
Drug: Digital messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital messaging therapy
Study: 37099376
Drug: TreadWill (unguided
Approvals — FDA: no, EMA: no, PMDA: no
Description: TreadWill (unguided computerized cognitive behavioral therapy)
Study: 37100160
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2)
Study: 37100205
Drug: Machine learning-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machine learning-based immune phenotyping (ML-derived immune phenotypes)
Study: 37100205
Drug: Concurrent KEAP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent KEAP1 and STK11 mutations in lung adenocarcinoma (LUAD)
Study: 37100349
Drug: 250-mg 17-hydroxyprogesterone
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-mg 17-hydroxyprogesterone caproate
Study: 37100349
Drug: 500-mg 17-hydroxyprogesterone
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg 17-hydroxyprogesterone caproate
Study: 37100349
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of 17-hydroxyprogesterone caproate
Study: 37100687
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake <150 μg/d
Study: 37100687
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake >550 μg/d
Study: 37100687
Drug: Daily iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily iodine intake at zero balance
Study: 37100687
Drug: Iodine intakes
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intakes <150 μg/d and >550 μg/d
Study: 37100705
Drug: 2-week placebo
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week placebo modulator study
Study: 37100705
Drug: 6-month placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month placebo modulator study
Study: 37100705
Drug: 2-week active-comparator
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week active-comparator modulator study
Study: 37100705
Drug: 6-month active-comparator
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month active-comparator modulator study
Study: 37100705
Drug: 2-week placebo
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week placebo inhaled antimicrobial study
Study: 37100705
Drug: 6-month placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month placebo inhaled antimicrobial study
Study: 37100891
Drug: Longer daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer daily eating window
Study: 37101251
Drug: Stimulant use
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant use (primarily meth)
Study: 37101251
Drug: Stimulant use
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant use
Study: 37101272
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (HFNC-O)
Study: 37101768
Drug: Erdafitinib (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (8 mg/d continuous in 28-d cycles, uptitration to 9 mg/d if serum phosphate <5.5 mg/dl)
Study: 37102598
Drug: KCd (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCd (weekly carfilzomib 70 mg/m2, cyclophosphamide, and dexamethasone)
Study: 37103493
Drug: StressProffen-CBI (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: StressProffen-CBI (Cognitive Behavioral Therapy Intervention)
Study: 37103532
Drug: Oral GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral GnRH antagonists (elagolix 300 mg twice daily with estradiol 1 mg and norethindrone 0.5 mg; relugolix 40 mg once daily with estradiol 1 mg and norethindrone 0.5 mg)
Study: 37103532
Drug: Oral GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral GnRH antagonists with menopausal replacement-level steroid hormones
Study: 37103915
Drug: Lumateperone, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumateperone, dosage and duration not available
Study: 37104481
Drug: Transdermal measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal measurement of FITC-sinistrin
Study: 37104748
Drug: Dose-escalated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated radiotherapy (RT) alone
Study: 37104748
Drug: Dose-escalated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated radiotherapy (RT) with short-term androgen deprivation (STAD)
Study: 37104758
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of margetuximab and pembrolizumab
Study: 37105210
Drug: Non-allogeneic HSCT
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-allogeneic HSCT therapy
Study: 37105689
Drug: Immunotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (specific types not detailed)
Study: 37105693
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) with very high neutralising antibody titre administered within 7 days of symptom onset plus standard of care
Study: 37106220
Drug: Mechanical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical stimulation of the efferent limb with 500 ml of saline chloride solution mixed with a thickening agent (Resource) for 2 weeks before ileostomy reversal.
Study: 37106319
Drug: M-TAPA block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-TAPA block (bupivacaine 0.25%, 25 ml)
Study: 37106319
Drug: OSTAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSTAP block (bupivacaine 0.25%, 25 ml)
Study: 37106343
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (intravenous propofol/ketamine/sodium thiopental)
Study: 37106559
Drug: Transdiagnostic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic group cognitive behaviour therapy (CBT)
Study: 37106559
Drug: Diagnosis-specific group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis-specific group cognitive behaviour therapy (CBT)
Study: 37107903
Drug: Usual clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual clinical treatment (UCT) without technology
Study: 37108484
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet (MD), specific details on dosage and duration not available.
Study: 37109303
Drug: Oral sodium-chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium-chloride capsules
Study: 37111136
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) supplement containing 440 mg of Fucoxanthin and Guarana
Study: 37111382
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) treatment
Study: 37113674
Drug: DREAMS 3G
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DREAMS 3G (third-generation drug-eluting resorbable magnesium scaffold)
Study: 37114054
Drug: EP/EC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP/EC plus PD-L1 inhibitor (historical control)
Study: 37114918
Drug: Implant-Based Reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-Based Reconstruction (IBR)
Study: 37115054
Drug: Pregabalin sustained-release
Normalized name: pregabalin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin sustained-release (SR) tablet (150 mg once a day)
Study: 37115054
Drug: Pregabalin immediate-release
Normalized name: pregabalin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin immediate-release (IR) capsule (75 mg twice a day)
Study: 37115132
Drug: No-implant interatrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-implant interatrial shunt
Study: 37115135
Drug: Goal doses
Normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Goofy Sun Smacker SPF 24 Berry Goal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal doses of beta-blockers
Study: 37115135
Drug: Goal doses
Normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Goofy Sun Smacker SPF 24 Berry Goal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal doses of ACEIs/ARBs/ARNIs
Study: 37115464
Drug: Mirogabalin 5-10
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 5-10 mg BID for 4 weeks, then 15 mg BID for 47 weeks, followed by tapering to once daily for 1 week.
Study: 37115464
Drug: Mirogabalin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin treatment for CNePSCI, CPSP, and CNePPD.
Study: 37115514
Drug: Selumetinib (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (continuous dosing, 1 cycle = 28 days)
Study: 37115514
Drug: Selumetinib (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (continuous dosing)
Study: 37115905
Drug: First ART
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First ART discontinuation and reaching a first undetectable pVL
Study: 37115908
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy plus growth hormone (GH) therapy
Study: 38536106
Drug: Photobiomodulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation Therapy
Study: 37116228
Drug: Kukoamine B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B (KB) at doses of 0.06, 0.12, or 0.24 mg/kg every 8 hours for 7 days
Study: 37116523
Drug: Quizartinib plus
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib plus chemotherapy
Study: 37116825
Drug: Curcumin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (600 mg Theracurmin HP daily for 30 days)
Study: 37116825
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 30 days)
Study: 37117085
Drug: Pharmaceutical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical therapy
Study: 37118696
Drug: Cough desensitization
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cough desensitization treatment (CDT)
Study: 37118703
Drug: Elevated cTnT
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated cTnT (≥ 14 ng/L) one year after the primary event
Study: 37119051
Drug: Enzalutamide (enza)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide (enza) + Leuprolide Acetate (LA) 160 mg/day
Study: 37119051
Drug: Enzalutamide monotherapy
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide monotherapy (mono)
Study: 37119829
Drug: Urinary DKK3
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary DKK3 above the median (>1689 pg/mg creatinine)
Study: 37119829
Drug: Intensified blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified blood pressure control in children with urinary DKK3 >1689 pg/mg creatinine
Study: 37119868
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for depression and smoking (12-week intervention)
Study: 37120027
Drug: Routine radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine radiation therapy with LLNs inside the clinical target volume (CTV)
Study: 37120027
Drug: Routine radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine radiation therapy with LLNs outside the clinical target volume (CTV)
Study: 37120027
Drug: Routine radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine radiation therapy with LLNs receiving ≥95% of planned dose
Study: 37120027
Drug: Routine radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine radiation therapy with LLNs receiving <95% of planned dose
Study: 37120027
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of 60 Gy
Study: 37120509
Drug: Pediatric Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Medication Therapy Management (pMTM) intervention
Study: 37120593
Drug: Venetoclax (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14) combined with azacitidine (75 mg/m2) and homoharringtonine
Study: 37120671
Drug: SRA737 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA737 800 mg QD
Study: 37120671
Drug: SRA737 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA737 1000 mg QD
Study: 37120671
Drug: SRA737 1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA737 1300 mg QD
Study: 37120671
Drug: SRA737 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA737 monotherapy
Study: 37120736
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once-daily
Study: 37120902
Drug: Daily enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily enteral lipid supplementation with arachidonic acid (AA):docosahexaenoic acid (DHA) (100:50 mg/kg/day)
Study: 37120902
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion containing olive oil:soybean oil (4:1)
Study: 37121237
Drug: Indobufen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (100 mg tablet twice per day)